Hoth Therapeutics Announces Participation at the American Society of Clinical Oncology (ASCO) Annual Meeting

About this update from Hoth Therapeutics, Inc.

[{"type":"text","content":"NEW YORK, May 24, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it will be an exhibitor at the American Society of Clinical Oncology (ASCO) Annual Meeting. Attendees will be able to visit the Hoth Therapeutics booth virtually starting May 24th through July 6, 2021. Hoth Therapeutics is dedicated to helping address unmet medical needs and improve the quality of life for patients living with rare cancers through the development of its assets, HT-001 and HT-KIT. \n\n \n \n \n \n \n \n\n \n\"We are excited to be given the opportunity to participate as an exhibitor at ASCO this year and add value to the oncology space,\" shared Robb Knie, Chief Executive Office of Hoth Therapeutics. \"Bringing innovative and novel therapeutics through development to address unmet patient needs continues to be our focus as we grow as a company.\"\nDetails on the therapeutics that will be discussed during the virtual exhibition are as follows:\nHT-KIT is a novel antisense oligonucleotide under development for the treatment of cancers resulting from aberrant KIT signaling. The HT-KIT drug is designed to more specifically target the receptor tyrosine kinase KIT, which is required for the proliferation, survival and differentiation of bone marrow-derived hematopoietic stem cells. Mutations in the KIT pathway have been associated with several human cancers, such as mast cell-derived cancers (aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL)), gastrointestinal stromal tumors, and acute myeloid leukemia. HT-001 is a topical formulation under development for the treatment of cutaneous toxicities associated with EGFR inhibitor therapy. EGFR inhibitors are critical cancer therapies for non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer, squamous-cell carcinoma of the head and neck, and breast cancer. However, nearly all patients receiving EGFR inhibitor therapy develop cutaneous adverse effects that can have a severe impact not only EGFR inhibitor discontinuation, but also patient quality of life. HT-001 is being specifically developed to treat the cutaneous toxicities associated with EGFR inhibitor therapy, such as acneiform rash, which there are no drugs specifically app...

More updates from Hoth Therapeutics, Inc.